Shanghai Topgen Pharmaceuticals
Latest round
- Series D
Last raised
- Jun 2022
Total raised
- $32M
Investors
- 4
About Shanghai Topgen Pharmaceuticals
Based in Shanghai, China, and established in 2012, Shanghai Topgen Pharmaceuticals operates as a biotechnology company that focuses on gene diagnosis, molecular science, cellular immunotherapy, and biopharmaceuticals mainly for the treatment of cancer. It has established branch sales offices in Zhejiang, Chongqing, Shandong, Jiangsu, Hubei, Henan, and Inner Mongolia. It has more than 800 cooperative hospitals and more than 40 medical laboratories. In January 2019, the company reached strategic cooperation with Illumina. In June 2018, it signed a strategic cooperation agreement with Wanfu Weikang. In February 2016, it was listed on the New Third Board. The company's business can be categorized into the tumor product line, chronic disease product line, infectious product line, maternal and child product line, and IVD product line. Its business covers more than 30 provinces. Some main business of the tumor product line category includes lung cancer, colorectal cancer, breast cancer, solid tumor, thyroid carcinoma, and gynecological tumor. The application fields include early screening, incidental diagnosis, genetic and gene detection Treatment monitoring, and other areas of diagnosis.
Who invested in Shanghai Topgen Pharmaceuticals
4 investors across 3 rounds
See all investors in Shanghai Topgen Pharmaceuticals
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Shanghai Topgen Pharmaceuticals
Who invested in Shanghai Topgen Pharmaceuticals?
Shanghai Topgen Pharmaceuticals has 4 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Shanghai Topgen Pharmaceuticals raised?
Shanghai Topgen Pharmaceuticals has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Shanghai Topgen Pharmaceuticals last raise money?
Shanghai Topgen Pharmaceuticals's most recent round on record is a Series D, in Jun 2022.
What does Shanghai Topgen Pharmaceuticals do?
Based in Shanghai, China, and established in 2012, Shanghai Topgen Pharmaceuticals operates as a biotechnology company that focuses on gene diagnosis, molecular science, cellular immunotherapy, and biopharmaceuticals mainly for the treatment of cancer.
Where is Shanghai Topgen Pharmaceuticals headquartered?
Shanghai Topgen Pharmaceuticals is headquartered in Shanghai, China.
Which VCs invest in companies like Shanghai Topgen Pharmaceuticals?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Shanghai Topgen Pharmaceuticals's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series D
Raising like Shanghai Topgen Pharmaceuticals? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.